{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"86.7","upperLimit":"94.9","value":"91.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"199"}],"units":"Participants"}],"description":"Per Response Evaluation Criteria in Solid Tumours (RECIST v1.1) assessed by MRI or CT: Complete Response (CR): Disappearance of all target and non-target lesions and no new lesions; Partial Response (PR): \\>= 30% decrease in the sum of diameters of Target Lesions (compared to baseline) and no new lesions; Stable disease (SD): Neither sufficient shrinkage to qualify as a response nor sufficient growth to qualify as progression; Progressive Disease (PD): \\>= 20% increase in the sum of diameters of TLs and an absolute increase in sum of diameters of \\>=5mm (compared to the previous minimum sum) or progression of NTLs or a new lesion. DCR is the percentage of patients with best response of CR, PR or SD (according to independent review), prior to progression (PD) or further anti-cancer therapy.","dispersionType":"95% Confidence Interval","groups":[{"description":"Daily single dose of AZD9291 80mg","id":"OG000","title":"AZD9291 80mg"}],"paramType":"NUMBER","populationDescription":"All patients who received at least 1 dose of study treatment and had measurable disease at baseline according to the independent review of baseline imaging data.","reportingStatus":"POSTED","timeFrame":"RECIST tumour assessments every 6 weeks from first dose until objective disease progression, up to approximately 11 months (at the time of analysis)","title":"Disease Control Rate (DCR)","type":"SECONDARY","unitOfMeasure":"% of participants"}